You are here: Home » PTI Stories » National » News
Business Standard

Orchid Pharma gets EIR from USFDA for its Chennai facility

Press Trust of India  |  New Delhi 

Drug firm today said it has received Establishment Inspection Report (EIR) from the US regulator for its facility.

The company has received the from the Food and Drug Administration (USFDA) on successful inspection closure for the post-marketing adverse drug experience reporting inspection (PADE) conducted at Nungambakkam, facility, said in a filing.

"The facility was inspected by USFDA in the month of June, 2017, it added.

As per the USFDA, after the completion of an inspection of a facility, an is issued to a company detailing inspectional findings.

of today closed 4.93 per cent higher at Rs 23.40 per scrip on

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, January 08 2018. 16:25 IST